title: Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
abstract: Although the prophylactic administration of indomethacin in extremely low-birth weight infants reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage, it does not appear to provide any long-term benefit in terms of survival without neurosensory and cognitive outcomes. Considering the increased drug-induced reduction in renal, intestinal, and cerebral blood flow, the use of prophylaxis cannot be routinely recommended in preterm neonates. However, a better understanding of the genetic background of each infant may allow for individualized prophylaxis using NSAIDs and metabolomics.
authors.affiliation: Neonatal Intensive Care Unit, Puericulture Institute And Neonatal Section, AOU University of Cagliari, Italy.
authors.forename: Vassilios
authors.initials: V
authors.lastname: Fanos
authors.forename: Michele
authors.initials: M
authors.lastname: Pusceddu
authors.forename: Angelica
authors.initials: A
authors.lastname: Dessì
authors.forename: Maria Antonietta
authors.initials: MA
authors.lastname: Marcialis
mesh_terms: D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004374:Ductus Arteriosus, Patent / Q000517:prevention & control*; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D007213:Indomethacin / Q000627:therapeutic use*; D052577:Infant, Extremely Low Birth Weight; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000517:prevention & control*; D020300:Intracranial Hemorrhages / Q000517:prevention & control; D008026:Ligation
chemical_list: D016861:Cyclooxygenase Inhibitors; D007052:Ibuprofen; D007213:Indomethacin